Extensive analysis of the T315I substitution and detection of additional ABL mutations in progenitors and primitive stem cell compartment in a patient with tyrosine kinase inhibitor-resistant chronic myeloid leukemia

References

• Druker BJ, Guilhot F, O'Brien SG, Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408–2417.
   PubMed Web of Science ®Google Scholar
• O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007;110:2242–2249.
   PubMed Web of Science ®Google Scholar
• Shah NP, Tran C, Lee FY, Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399–401.
   PubMed Web of Science ®Google Scholar
• Weisberg E, Manley PW, Breitenstein W, Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7:129–141.
   PubMed Web of Science ®Google Scholar
• Gorre ME, Mohammed M, Ellwood K, Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876–880.
   PubMed Web of Science ®Google Scholar
• Soverini S, Iacobucci I, Baccarani M, Martinelli G. Targeted therapy and the T315I mutation in Philadelphia-positive leukemias. Haematologica 2007;92:437–439.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Cortes J. Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. Clin Cancer Res 2008;14:4392–4399.
   PubMed Web of Science ®Google Scholar
• Azam M, Seeliger MA, Gray NS, Kuriyan J, Daley GQ. Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol 2008;15:1109–1118.
   PubMed Web of Science ®Google Scholar
• Pricl S, Fermeglia M, Ferrone M, Tamborini E. T315I-mutated Bcr-Abl in chronic myeloid leukemia and imatinib: insights from a computational study. Mol Cancer Ther 2005;4:1167–1174.
   PubMed Web of Science ®Google Scholar
• Mian AA, Schull M, Zhao Z, The gatekeeper mutation T315I confers resistance against small molecules by increasing or restoring the ABL-kinase activity accompanied by aberrant transphosphorylation of endogenous BCR, even in loss-of-function mutants of BCR/ABL. Leukemia 2009;23:1614–1621.
   PubMed Web of Science ®Google Scholar
• Coulombel L, Kalousek DK, Eaves CJ, Gupta CM, Eaves AC. Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. N Engl J Med 1983;308:1493–1498.
   PubMed Web of Science ®Google Scholar
• Holyoake TL, Jiang X, Drummond MW, Eaves AC, Eaves CJ. Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia. Leukemia 2002;16:549–558.
   PubMed Web of Science ®Google Scholar
• Tourino C, Pflumio F, Novault S, Efficient ex vivo expansion of NOD/SCID-repopulating cells with lympho-myeloid potential in hematopoietic grafts of children with solid tumors. Hematol J 2001;2:108–116.
   PubMedGoogle Scholar
• Gabert J, Beillard E, van der Velden VH, Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003;17:2318–2357.
   PubMed Web of Science ®Google Scholar
• Beillard E, Pallisgaard N, van der Velden VH, Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe Against Cancer program. Leukemia 2003;17:2474–2486.
   PubMed Web of Science ®Google Scholar
• Branford S, Cross NC, Hochhaus A, Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia 2006;20:1925–1930.
   PubMed Web of Science ®Google Scholar
• Chomel JC, Sorel N, Bonnet ML, Quantitative monitoring of the T315I mutation in patients with chronic myeloid leukemia (CML). Leuk Res 2009;33:551–555.
   PubMed Web of Science ®Google Scholar
• Sorel N, Chazelas F, Brizard A, Chomel JC. Double-gradient-denaturing-gradient gel electrophoresis for mutation screening of the BCR-ABL tyrosine kinase domain in chronic myeloid leukemia patients. Clin Chem 2005;51:1263–1266.
   PubMed Web of Science ®Google Scholar
• Thijsen SFT, Schuurhuis GJ, van Oostveen JW, Theijsmeijer AP, Langenhuijsen MMAC, Ossenkoppele GJ. Molecular analysis of hematopoietic colonies derived from chronic myeloid leukemia patients: interphase fluorescence in situ hybridization compared with RT-PCR. Leukemia 1997;11:301–305.
   PubMed Web of Science ®Google Scholar
• Sorel N, Bonnet ML, Guillier M, Evidence of ABL-kinase domain mutations in highly purified primitive stem cell populations of patients with chronic myelogenous leukemia. Biochem Biophys Res Commun 2004;323:728–730.
   PubMed Web of Science ®Google Scholar
• Chu S, Xu H, Shah NP, Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 2005;105:2093–2098.
   PubMed Web of Science ®Google Scholar
• Udomsakdi C, Eaves CJ, Swolin B, Rapid decline of chronic myeloid leukemic cells in long-term culture due to a defect at the leukemic stem cell level. Proc Natl Acad Sci USA 1992;89:6192–6196.
   PubMed Web of Science ®Google Scholar
• Lataillade JJ, Clay D, David C, Phenotypic and functional characteristics of CD34+ cells are related to their anatomical environment: is their versatility a prerequisite for their bio-availability? J Leukoc Biol 2005;77:634–643.
   PubMed Web of Science ®Google Scholar
• Eaves CJ, Eaves AC. Stem cell kinetics. Baillieres Clin Haematol 1997;10:233–257.
   PubMed Web of Science ®Google Scholar
• Nicolini FE, Corm S, Le QH, Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC Group). Leukemia 2006;20:1061–1066.
   PubMed Web of Science ®Google Scholar
• Ernst T, Hoffmann J, Erben P, ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica 2008;93:1389–1393.
   PubMed Web of Science ®Google Scholar
• Curvo RP, Zalcberg IR, Scholl V, A recurrent splicing variant without c-ABL exon 7 in imatinib-resistant patients. Leuk Res 2008;32:508–510.
   PubMed Web of Science ®Google Scholar
• Misyurin AV, Suchkova MV, Krutov AA, There are not only point mutations but also splicing defects in BCR-ABL gene in Cml patients treated by imatinib. Haematologica 2008;93(Suppl. 1): Abstract 0555.
   Google Scholar
• Azam M, Nardi V, Shakespeare WC, Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. Proc Natl Acad Sci USA 2006;103:9244–9249.
   PubMed Web of Science ®Google Scholar
• Jiang X, Saw KM, Eaves A, Eaves C. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. J Natl Cancer Inst 2007;99:680–693.
   PubMed Web of Science ®Google Scholar
• Stoklosa T, Poplawski T, Koptyra M, BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations. Cancer Res 2008;68:2576–2580.
   PubMed Web of Science ®Google Scholar
• Fanta S, Sonnenberg M, Skorta I, Pharmacological inhibition of c-Abl compromises genetic stability and DNA repair in Bcr-Abl-negative cells. Oncogene 2008;27:4380–4384.
   PubMed Web of Science ®Google Scholar